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Summary Both soluble and nuclear oestrogen receptors have been measured in at least two separate sections
from 72 endometrial. cancers and 12 normal endometria. Concentration of oestrogen receptor is shown to be,
in our hands, more meaningful when expressed per unit DNA than per unit protein, whether for soluble or
nuclear receptor. Endometrial cancer cells from the central part of the tumour are shown to be receptor
negative more frequently than those from peripheral tumour. Thus, in large cancers, biopsies from different
areas are required before a tumour can be correctly designated as receptor positive, heterogeneous or receptor
negative. The intratumoral variation of receptor status may relate to poor prognosis, since patients with
homogeneous receptor-positive disease survive significantly longer than those with tumours showing either
heterogeneous distribution of receptor or homogeneous absence of receptor. Intratumoral variation in
receptor status is found to be more common in the group of patients who are within 7 years of their
menopause, than in older patients.
In Sicily, the incidence of endometrial cancer is increasing.
Standardized mortality rate, per 100,000 women, was 9.66
for endometrial cancer (Cislaghi et al., 1978). However, this
rate is thought to be an underestimate (Castagnetta et al.,
1980). Further, endometrial cancer clinics in Palermo have
recently seen a rapid increase in new cases. For this reason,
better indices of prognosis and therapy selection are
required. The relative frequency of locally advanced disease
in Sicily provides adequate tissue for an appropriate study.
The value of the steroid receptor status in the management
of endometrial cancer has recently been reviewed (Soutter &
Leake, 1987).
The first studies of oestrogen receptor content (in breast
cancer) were confined to the soluble fraction (Jensen et al.,
1973; Mass et al., 1975). However, a significant proportion
of tumours may contain non-functional receptor in the
soluble fraction (Laing et al., 1977; Spelsberg & Boyd-
Leinen, 1980). Improved prediction of response to endocrine
therapy has been achieved through measuring nuclear
oestrogen receptor (Barnes et al., 1979; Hahnel et al., 1980;
Leake et al., 1981a), progesterone receptor (Bloom et al.,
1980; Hawkins et al., 1980; Osborne et al., 1980) a product
of oestrogen action, oestrogen-induced enzyme activity
(Duffy & O'Connell, 1981) and oestrogen-induced protein
secretion (Veith et al., 1983). We have selected nuclear
oestrogen receptor because this assay is relatively easy,
oestrogen nuclear receptor is relatively stable and the
amount of tissue needed is relatively small (Leake et al.,
1981a).
In this paper, we report the measurement of soluble and
nuclear oestrogen receptor content of biopsies from both the
centre and the edge of locally advanced endometrial cancers.
Evidence is presented that the results are best expressed
relative to the DNA content of the original suspension.
Using this approach, we have examined the significance of
intratumoral variation of receptor content in relation to the
subsequent behaviour of the disease.
Materials and methods
Patients
Seventy-two patients were included in the study. All attended
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the Gynaecologic Clinics of the City Hospital, the University
Hospital or the Cancer Hospital Centre, Palermo. Of the 72,
8 patients were pre-menopausal (mean age 44.6yr), 19 were
less than seven years post-menopausal (mean age 54.9) and
45 were more than 7 years post-menopausal (mean age 66.7).
Menopause was taken as the time of the last menstrual
bleed.
Tissue collection and storage
Tissue was collected, on ice, fresh from the operating theatre.
Adhering fat and obviously necrotic tissue was removed
before adjacent sections were taken for pathological
examination and oestrogen receptor assay. Separate sections
were removed from the edge and the more central part of
the tumour. Tissue was either processed fresh or stored at
-20°C in sucrose-glycerol buffer [0.25 M sucrose,
10mM HEPES, 1.5mM MgCl2, pH 7.4, 50% glycerol(v/v)].
Under these conditions of storage, concentration of both
soluble and nuclear oestrogen receptor has been shown to be
stable for at least three months in both breast and
endometrial cancer biopsies (Leake et al., 1979; Crawford et
al., 1984). The molecular form of the receptor, as determined
by sucrose density gradient analysis, is also stable under
these storage conditions for 60-90 days (Crawford et al.,
1984). Normal tissue was obtained from pathologically
normal.regions of hysterectomy samples.
Tissuefractionation
Stored tissue was re-hydrated for 15min at 4°C in sucrose
buffer (0.25M sucrose, 10mmHEPES, 1.5mmMgCl2,
pH 7.4). A section of approximately 150mg tissue was
homogenised in freshly-made HED buffer (20mmHEPES,
1.5mm EDTA, 0.25mm Dithiothreitol, pH7.4) at 50mgml-1
for 2 x 10sec bursts at a setting of 150 on an Ultra-Turrax
model TP 18/2. The homogenate was examined under the
phase-contrast microscope and further homogenised, as
necessary, in a glass tissue grinder (Kontes Duall) until
- 80% of the cells were lysed. At no stage was the
temperature of the homogenate permitted to rise above 4°C.
Normal tissue was adequately homogenised in a teflon-glass
homogeniser. The homogenate was centrifuged at 5,000g for
10min at 4°C to yield a cytosol and a crude nuclear pellet.
The pellet was washed three times in buffered saline (0.15M
NaCl, 10mMHEPES, pH7.4) and finally resuspended, using
the Kontes grinder, to the original volume in buffered saline.
Incorporation at this stage of a wash in 0.1% Triton X-100
did not significantly reduce the level of nuclear binding.
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Further purification of the nuclear pellet by differential
centrifugation through sucrose (final layer was 2.4M sucrose)
did not alter receptor content per unit DNA.
Receptor measurement
Incubation of either the cytosol or nuclear pellet with
3H-oestradiol (+ 100-fold excess diethylstilboestrol as
competitor) was carried out at seven concentrations in the
range 10 - 10-9 M. All tubes were incubated at 4°C for
18 h or 20°C for 2h, both conditions give similar receptor
content (Love et al., 1983).
Unbound steroid was removed from the cytosol (DCC)
and nuclear fractions (filtration through Whatman GF/C
discs) as previously described (Leake, 1980). Results were
analysed by the method of Scatchard using a simple
computer programme (written for the Olivetti M20).
Receptor content was only reported as positive if at least
five points could be used to determine a 'best fit' line and
if the dissociation constant (Kd) lay in the range
5 x 10- "-1 5 x 10- 10 M. Intra-assay variation was within 5%
(six separate samples) and inter-assay variation within 12%
(ten separate assays) using lyophilized quality control
samples of human myometrium and endometrial cancer.
Protein and DNA content were determined by the
methods of Lowry (Lowry et al., 1951) and Burton (as
modified by Katzenellenbogen and Leake, 1974),
respectively.
Results
Expression ofreceptor concentration
Quantitative data on receptor content of breast and
endometrial tumours varies considerably between
laboratories (Cowan & Leake, 1984). For soluble oestrogen
receptor, this is, in part, due to the large variations in
estimation of protein content of similar cytosols. Use of
DNA content as a reference point for soluble oestrogen
receptor content has been proposed since it is less sensitive
to assay reagents such as dithiothreitol and molybdate. In
normal endometrium, goodness of fit to a normal
distribution of soluble oestrogen receptor was P<0.001
relative to protein but 0.5<P<0.75 relative to DNA.
Similar results were obtained with tumour tissue. Thus
statistical comparison of receptor content of different groups
of tissue is best made when receptor concentration is referred
to the DNA content of the original homogenate.
Cellularity and histology
Grade I tumours contained 25-50% tumour cells. Less well
differentiated tumours were more highly cellular, with grade
III tumours containing 40-75% tumour cells. Within any
one histological grade, tumours that were uniformly
oestrogen receptor positive were associated with lower
cellularity than those which had both receptor positive and
receptor negative components. As reported previously
(Castagnetta et al., 1983), the proportion of grade III
tumours is higher in Sicily than elsewhere.
Receptor content
The mean receptor content of the 56 receptor positive
samples taken from the edge of each tumour is shown in
Table I. Relative receptor content of a small group of
histologically normal endometrium is also shown. The mean
concentration of receptor in either soluble or nuclear fraction
was very similar to that of normal secretory endometrium,
whether expressed per unit protein or DNA. For review of
the change in receptor content of the normal endometrium
during the menstrual cycle (Soutter & Leake, 1987).
Distribution ofreceptor
For each patient, receptor status was determined in both the
soluble and nuclear fractions of at least two separate parts
of the tumour. Thus, an individual tumour was classified as
(+ +) if both soluble and nuclear oestrogen receptor were
present in all sections of the tumour examined. If receptor
was missing from either soluble or nuclear fraction of one
biopsy, then the tumour was (+ -) and if receptor was
absent from all fractions, then the tumour was classified as
(- -). Using this classification, receptor status of tumours
from the 72 patients can be summarised as shown in Figure
1. The data indicate that loss of receptor from one fraction
(+ -) is more common in the early post-menopausal group
(7 out of 19; 37%) than in the late menopausal group (5 out
of 45; 11%). This difference is statistically significant (X2test:
0.05>P>0.025).
Intratumoral variations in receptor content
Table II shows the mean data for all receptor positive
biopsies taken from either the periphery or the more central
(presumably older) part of the tumour for the 51 patients in
the follow-up study (see later). The concentrations are
similar to those previously reported for locally advanced
endometrial cancer (Billiat et al., 1982). Soluble receptor was
found in 51% of biopsies from the central portion (26 out of
51) and in 67% from the periphery (34 out of 51). Although
the incidence of receptor positive tissue was lower in the
central portions, the concentration of receptor within
receptor-positive cells from either the central or peripheral
portions was statistically indistinguishable. The apparent
increase in loss of receptor from the central portion is
unlikely to be due to cell necrosis since (a) obviously necrotic
areas were removed before assay, and (b) pathology of the
adjacent section was checked carefully during the
determination of cellularity.
Relation ofreceptor distribution to clinical progress
Only those patients for whom full FIGO classification
(UICC-TNM, 1974) was possible, were included in the
follow-up study. However, this sub-group of 51 patients was
identical to the original 72 in terms of distribution between
Table I Oestrogen receptor content of normal secretory endometrium and endometrial
cancer
Cytosol
Nuclear
%ER+ fmolmg-'Pr. fmolg-'DNA fmolpg- DNA
Normal
n= 12 100 68.1+45.3 2.1+1.0 1.9+1.4
Endometrial cancer
n=72 75 62.4+44.2 2.4+1.9 2.1+1.4
All values in the tables are expressed as Mean+S.D. The endometrial cancer values
are the means of all oestrogen receptor positive samples taken from the peripheral
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Table III Follow-up study of 51 adenocarcinoma
patients having 55 months mean follow-up
Year Total HS Status Alive Dead
1980 12 (+ +) 9 3
n=23 5 (-) 3 2
6 (+-) 4 2
1981 9 (+ +) 7 2
n= 18 8 (-) 6 2
1 (+-) 1 0
1982 4 (+ +) 3 (1*)
n=10 4 (--) 3 1
2 (+ -) 1 1
*This patient died from a diabetic coma. Year indicates
year of presentation.
time for the five patients with (+ +) tumours was
26.0+ 11.5mo., whereas that for the three in the (+ -)
group was 8.33 +2.5mo. The two groups appeared
equivalent in terms of histological grade (almost all grade II)
and extent of myometrial invasion.
Discussion .5
Figure 1 The distribution of patients among the three receptor
status groups is shown relative to menstrual status. Group 1
(n=8) is pre-menopausal, Group 2 (n = 19) is <7yr post-
menopausal and Group 3 (n =45) is >7yr post-menopausal.
Uniform receptor positive status (+ +) is indicated by Cl,
variable status (+ -) by IH and uniform receptor negative status
(--) by E.
Table II Mean concentration of soluble and nuclear oestrogen
receptor in endometrial cancer biopsies in relation to menopausal
status
Cytosol
Menopausal Nuclear
status fmolmg 1 Pr. fmoljug- I DNA fmol ig1 DNA
Pre
C n=2 50.0+46.7 1.4+2.0 1.5+1.5
P n =3 48.2+48.8 2.3 +4.8 2.3 +2.2
Post <7yr
C n=6 110.8+92.3 3.3+4.6 2.0+1.6
P n=9 56.3+43.1 1.1 + 1.0 1.5+1.3
Post >7yr
C n= 18 63.1+46.1 2.1+2.0 1.6+1.7
P n=22 60.9+48.8 2.3+2.4 1.6+1.3
C=central or older portion of tumour. P=peripheral portion of
tumour. Numbers of tumours (n) reflect the number of receptor
positive biopsies in each category. This Table is confined to the 51
patients included in the follow-up study of whom 4 were pre-
menopausal, 13 were post-menopausal <7yr and 34 post-
menopausal >7yr.
the various receptor classes (49% (+ +) in both cases, 33%
instead of 32% in the (--) group and 17% instead of 18%
in the (+ -) group). The division by menopausal status (4
pre-menopausal, 13 early post-menopausal and 34 more than
7yr post-menopausal) was also similar, although the pre-
menopausal group is now too small for further analysis.
The clinical follow-up of the 51 patients is shown in Table
III. The mean follow-up time of those still alive was 55
months (range 36-69mo.) The mean survival time for the 14
dead was 16.71 mo. One patient in the (+ +) group died
from non-cancer-related disease (diabetic coma). Of those
who have died from endometrial cancer, the mean survival
The accepted method for expression of soluble receptor
content is relative to protein content of the tissue. Even in
normal endometrium however, this leads to an abnormal or
skewed distribution of the data. For this reason, receptor
values may be more comparable when expressed relative to
DNA content of the original suspension, even if only soluble
receptor content is being determined.
In larger tumours, not only can receptor content vary
across a tumour (Leake et al., 1979) but even receptor status
can vary from positive to negative across individual tumours
(Figure 1). The follow-up of the patients (Table III) indicates
the possible clinical significance of a heterogenous receptor
distribution across a tumour. Clinically, it is not easy to
determine whether an advanced local tumour is slow
growing or aggressive. Multiple biopsies of such a tumour
for determination of functional receptor status may be
useful. Those tumours which are receptor positive
throughout, reflect a relatively good prognosis, whereas
variation in receptor status across the tumour may be
associated with poor prognosis. In conclusion, assay of
functional receptors (measured as soluble and tightly bound
receptor in the homogenate) from different parts of large
endometrial cancers may be a measure of both hormone
sensitivity and prognosis.
Antibodies to oestrogen receptor have the potential to
reveal the extent of heterogeneity of receptor distribution in
any tumour (Crawford et al., 1985; King et al., 1985).
However, until their value has been fully assessed, the
biochemical approach, described here, remains the best way
to detect heterogeneous tumours. The optimal therapy for
tumours heterogeneous in receptor status may well differ
from that for homogeneous receptor positive tumour in that
some combination or, rather, sequence of endocrine and
chemotherapy may be more appropriate for the former type
of tumour.
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